The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...

The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t gotten worse after getting platinum-based chemo and radiation at the same ...

The FDA has approved Imfinzi (durvalumab) to treat LS-SCLC that has not progressed after concurrent platinum-based chemotherapy and radiation.

Eli Lilly’s LLY popular obesity drug, Zepbound showed better weight loss than Novo Nordisk’s Wegovy in a head-to-head study.

IMFINZI ® (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumor’s immune-evading tactics ...

Durvalumab was associated with a 27% reduction in the risk for death compared with placebo in the phase 3 ADRIATIC trial.

AstraZeneca's Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small ...